Welcome to our dedicated page for Carparts Com SEC filings (Ticker: PRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CarParts.com keeps more than a million aftermarket SKUs moving through a tightly managed fulfillment network, yet the story behind those logistics lives deep inside its SEC reports. If you have ever wondered where to find CarParts.com’s quarterly earnings report 10-Q filing or how shipping costs flow through cost of goods sold, this page has every disclosure in one place.
Stock Titan’s AI turns dense documents into clear insights. Open a 250-page CarParts.com annual report 10-K simplified and our platform highlights inventory turnover, warehouse lease commitments, and segment margin shifts in plain language. Need real-time alerts? We stream CarParts.com Form 4 insider transactions real-time so you can track CarParts.com insider trading Form 4 transactions the moment executives act. Material developments like new distribution centers arrive as CarParts.com 8-K material events explained, while the CarParts.com proxy statement executive compensation spells out how leadership is rewarded for e-commerce growth.
Whether you’re monitoring CarParts.com earnings report filing analysis, comparing gross margin notes across periods, or simply understanding CarParts.com SEC documents with AI, you’ll find every form—from 10-Q to S-8—in one continuously updated feed. Typical use cases include:
- Reviewing segment revenue before adding PRTS to a portfolio
- Watching CarParts.com executive stock transactions Form 4 for confidence signals
- Flagging supply-chain expansions disclosed in 8-Ks
Form 4 filing overview: On 06/30/2025, MAIA Biotechnology, Inc. (ticker MAIA) granted director Cristian Luput a package of stock options under the company’s 2021 Equity Incentive Plan.
- Options granted: 21,350 options to purchase common shares.
- Exercise price: $1.80 per share.
- Vesting schedule: 100% vested immediately on the grant date.
- Expiration: 06/30/2035 (10-year term).
- Post-transaction holdings: Luput now holds 21,350 derivative securities directly.
No non-derivative share transactions were reported, and the filing was made individually by the director. The grant represents routine equity compensation designed to align director incentives with shareholder value, but it modestly increases the company’s fully diluted share count.